Ginkgo Bioworks Holdings Inc vs Iris Energy Limited — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Iris Energy Limited trades at $38.9 (market cap $13.80B). The key difference: Iris Energy Limited is far larger — about 23.4× Ginkgo Bioworks Holdings Inc's market cap. Which is the better fit depends on your goals.
| DNA | IREN | |
|---|---|---|
Market Cap | $590.53M | $13.80B |
Sector | Health | Energy |
52-Week High | $16.14 | $76.41 |
52-Week Low | $5.48 | $15.40 |
Enterprise Value | $627.78M | $15.55B |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
IREN trades at $38.98, down 5.18% on the day, amid a bearish technical signal and recent earnings misses. The company is transitioning from Bitcoin mining to AI infrastructure, showing strong revenue growth projections for 2026 ($757M) and a net income margin improvement to 20.87%. However, negative ROE and ROA highlight profitability challenges. Analyst consensus remains bullish with a $79.11 price target, but high valuation ratios (P/E 50.14, P/S 14.99) suggest premium pricing.
The outlook hinges on successful execution of AI cloud expansion, with key risks including competitive pressures from Meta's cloud ambitions and operational scalability. Investors face a high-risk, high-reward scenario, balancing analyst optimism against technical weakness and recent stock volatility. Near-term catalysts include potential contracts and capacity milestones, but misses on earnings expectations warrant caution.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →